Bupa offers personalised preventive care supported by genomics
In a first for private medical insurers, Bupa is rolling out new DNA-driven prevention pathways, marking its ongoing transition from a traditional reactive insurer to a proactive health partner. The initiative introduces clinical pathways for breast cancer, cardiovascular disease, and diabetes that are guided by genetic risk assessments. By integrating genomic data with clinical support and follow-up care, Bupa becomes…